Index by category›
Research area
Recovery & injury
Peptides studied in the context of tissue repair, tendon and ligament healing, inflammation, and wound recovery.
Several peptides are studied in the context of tissue repair and recovery: healing of tendons, ligaments, muscle, skin, and the gut lining. This is one of the most popular areas of interest, and also one where the gap between online claims and actual evidence is widest.
The honest summary: the recovery peptides documented here are predominantly supported by laboratory and animal research, not human clinical trials. BPC-157 and TB-500 are the two most commonly discussed (and often used together), but neither has completed human trials of the marketed compound, and both are research chemicals that are not approved for human use. KPV is a small anti-inflammatory fragment studied mainly in cell and animal models of gut and skin inflammation. GHK-Cu has the most human data of this group, but that evidence is largely topical/cosmetic (skin), not injectable repair.
Evidence is mostly preclinical
For most "recovery" peptides, the mechanistic and animal data are interesting but human efficacy and long-term safety are not established. Claims that any of these is a proven human therapy go beyond the published research. None of the unapproved compounds here should be assumed safe or effective in people.
Browse the individual entries below for the specific mechanisms, the studies behind them, their regulatory status, and honest safety notes. Nothing here is medical advice.
Conditions people ask about
Popular videos and peptide-vendor guides in this area promise to "reverse", "heal", or "cure" chronic pain and joint damage with a peptide protocol. That framing is not supported: no compound on this site is an approved treatment for any condition below, and dramatic reversal claims lack controlled human evidence. The notes below exist to answer common searches honestly — not to recommend a protocol. Any of these conditions is a matter for a licensed clinician and proper diagnosis; a research peptide is not a substitute for that care.
Fibromyalgia
Popular videos and peptide-vendor guides frame fibromyalgia as a chronic-pain condition you can "manage" or "calm" with a peptide protocol, pointing to BPC-157's reported effects on serotonin, dopamine, and inflammation as if they translated into human pain relief. The evidence reality: no peptide is an approved treatment for fibromyalgia, and there are no controlled human trials of any peptide with fibromyalgia as an endpoint. The mechanistic story — modulation of dopaminergic and serotonergic signalling and downregulation of TNF-alpha/IL-6 — comes entirely from animal models [Animal]; whether any of it produces symptom relief in people is untested [Hypothesis]. Fibromyalgia is a real diagnosis that needs a licensed clinician; a research peptide is not a substitute. In this context the community discusses BPC-157, an unapproved research peptide whose fibromyalgia rationale (serotonin/dopamine modulation, lowered TNF-alpha and IL-6) is animal-only [Animal] with no human trial for fibromyalgia or any chronic-pain condition; KPV, a small anti-inflammatory fragment (the C-terminal tail of alpha-MSH) studied only in cell and animal models of inflammation [In vitro][Animal], often paired with BPC-157 on that anti-inflammatory rationale with no controlled human evidence for fibromyalgia; and TB-500, an unapproved thymosin-beta-4 fragment marketed for "recovery" whose documented tissue-repair and angiogenesis effects are animal-only [Animal], with no human evidence for fibromyalgia. Discussed, not proven.
Osteoarthritis / joint pain
High-claim content presents intra-articular BPC-157 (often stacked with TB-500) as a way to "heal" arthritic joints and "regrow cartilage", citing a knee-injection study as if joint degeneration were reversible with a peptide protocol. The evidence reality: no peptide is an approved treatment for osteoarthritis or joint pain. The single piece of human data usually cited is a small retrospective case series (12 patients) of intra-articular BPC-157 for chronic knee pain, described in a 2025 systematic review (Vasireddi et al.) — uncontrolled, no placebo group, and not a randomized controlled trial, so it cannot establish efficacy or that cartilage regenerates [Human, low quality]; the cartilage-regeneration and anti-inflammatory rationale is otherwise preclinical [Animal][In vitro]. Osteoarthritis needs proper imaging and a licensed clinician; a research peptide is not a substitute. Compounds discussed here are BPC-157, whose only human joint data is that small uncontrolled retrospective knee series [Human, low quality] — it reported pain relief in some individuals but cannot prove efficacy or cartilage repair, with broader claims resting on animal tendon/tissue models [Animal]; TB-500, an unapproved thymosin-beta-4 fragment frequently paired with BPC-157 in the recovery context, whose cartilage-relevant effects (angiogenesis, stem-cell mobilization) are preclinical [Animal][In vitro] and which has no human clinical trials of the marketed fragment; Thymosin beta-4, the parent regenerative peptide behind TB-500, studied for tissue repair and angiogenesis in animal and cell models [Animal][In vitro] and reaching only small early-stage human trials for other indications (ophthalmic and systemic), with any cartilage benefit extrapolated as a hypothesis [Hypothesis] and no controlled human evidence for osteoarthritis; and GHK-Cu, a copper peptide with the most human data of this group — but that evidence is topical/cosmetic skin work [Human, skin only], with joint mentions extrapolating its remodeling/anti-inflammatory rationale and no controlled human evidence for osteoarthritis.
5 peptides studied in this area
BPC-157
Body Protection Compound-157
A synthetic pentadecapeptide whose sequence derives from a protein found in human gastric juice, studied almost entirely in animal models for tissue repair, tendon and ligament healing, gastrointestinal protection, and angiogenesis. It is not approved for human use, and rigorous human trial data are essentially absent.
TB-500
TB500
A synthetic peptide marketed as a fragment of thymosin beta-4 (Tβ4). Analytical work identifies the material sold as "TB-500" as the N-terminal acetylated 17–23 fragment of Tβ4 (Ac-LKKTETQ), the protein's actin-binding motif. Most biological evidence describes full-length Tβ4 in animals and cell culture, not the TB-500 fragment, and there are no human clinical trials of TB-500 itself. It is not approved for human use and is prohibited in sport.
Thymosin beta-4
Tβ4
A naturally occurring 43-amino-acid actin-sequestering peptide that is among the most abundant intracellular peptides in mammalian cells, with studied roles in cell migration, angiogenesis, wound healing, and corneal and cardiac repair. It has been developed as the investigational drug candidates RGN-259 (ophthalmic) and RGN-352 (systemic injectable) in small, early-stage human trials, none of which has yielded an approved product. It is distinct from the marketed fragment TB-500 (Ac-LKKTETQ) and is prohibited in sport.
KPV
Lys-Pro-Val
A tripeptide corresponding to the C-terminal sequence of α-MSH (residues 11–13), studied in vitro and in animal models for anti-inflammatory activity in intestinal and dermal inflammation. Not approved for human use.
GHK-Cu
Copper tripeptide-1
GHK-Cu is the copper(II) complex of the naturally occurring human tripeptide glycyl-L-histidyl-L-lysine (GHK). Plasma GHK declines with age, and the complex has well-documented roles in wound healing, collagen and extracellular-matrix synthesis, antioxidant defense, and broad gene-expression modulation. It is widely used and regarded as safe as a topical cosmetic ingredient, with some supportive human skin studies; injectable "research" use has no human trial evidence.